Celldex Therapeutics (CLDX) vs Insight Molecular Diagnostics (IMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Celldex Therapeutics (CLDX) has outperformed Insight Molecular Diagnostics (IMDX) over the past year, gaining 16.1% versus a loss of 6.0%. Over five years, CLDX leads with a -34.1% price change compared with -94.9% for IMDX. Celldex Therapeutics is the larger company by market cap ($2.30 billion vs $105.4 million), about 21.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDX | IMDX |
|---|---|---|
| Share price | $29.34 | $3.22 |
| Market cap | $2.30B | $105.37M |
| 1-day change | -3.58% | -6.95% |
| YTD return | +12.04% | -53.87% |
| 1-year return | +16.06% | -5.98% |
| 5-year return | -34.11% | -94.91% |
| EPS (TTM) | $-4.35 | $-1.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54M | — |
| Revenue growth (YoY) | -77.99% | — |
| Net income (latest FY) | $-258.76M | — |
| Gross margin | 87.06% | — |
| Operating margin | -18599.81% | — |
| Net margin | -16748.03% | — |
| 52-week high | $45.14 | $8.51 |
| 52-week low | $22.10 | $2.42 |
| Distance from 52-week high | -35.00% | -62.16% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +114.96% | — |
| Average volume | 1.27M | 233.13K |
| Shares outstanding | 78.53M | 32.72M |
| Employees | 198 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Celldex Therapeutics is about 21.9 times larger than Insight Molecular Diagnostics by market value ($2.30B vs $105.37M).
- CLDX has outperformed IMDX by 22.0 percentage points over the past year.
About Celldex Therapeutics
CLDX stock →Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 198 employees
CLDX vs IMDX FAQ
Which is bigger, Celldex Therapeutics or Insight Molecular Diagnostics?
Celldex Therapeutics (CLDX) is larger, with a market capitalization of $2.30B compared with $105.37M for Insight Molecular Diagnostics (IMDX).
Which stock has performed better over the past year, CLDX or IMDX?
CLDX returned +16.06% over the past 12 months, compared with -5.98% for IMDX (price return, excluding dividends). Past performance does not predict future results.
Are Celldex Therapeutics and Insight Molecular Diagnostics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.